Base de dados : MEDLINE
Pesquisa : D02.092.471.683.152.766 [Categoria DeCS]
Referências encontradas : 760 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 76 ir para página                         

  1 / 760 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773937
[Au] Autor:Ryder JR; Kaizer A; Rudser KD; Gross A; Kelly AS; Fox CK
[Ad] Endereço:Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA.
[Ti] Título:Effect of phentermine on weight reduction in a pediatric weight management clinic.
[So] Source:Int J Obes (Lond);41(1):90-93, 2017 Jan.
[Is] ISSN:1476-5497
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Phentermine is the most widely prescribed obesity medication in adults, yet studies of its use in the pediatric population are limited. We conducted a retrospective chart review of adolescents with obesity treated in a pediatric weight management clinic to examine the weight loss effectiveness of phentermine added to standard of care (SOC) lifestyle modification therapy versus SOC alone. All patients receiving phentermine plus SOC (n=25) were matched with a comparison group receiving only SOC (n=274). Differences at 1, 3 and 6 months were evaluated using generalized estimated equations adjusting for age, sex and baseline body mass index (BMI) and robust variance standard error estimates for confidence intervals and P-values. Phentermine use was associated with a greater percent change in BMI at 1 month (-1.6%; 95% confidence interval (CI): -2.6, -0.6%; P=0.001), 3 months (-2.9%; 95% CI: -4.5, -1.4%; P<0.001) and 6 months (-4.1%; 95% CI: -7.1, -1.0%; P=0.009) compared with SOC alone, with no differences in systolic or diastolic blood pressure between groups. Heart rate was higher at all time-points in the phentermine plus SOC compared with SOC-only group. These data suggest that short-term use of phentermine added to SOC may enhance weight loss in adolescents with obesity in the clinical setting.
[Mh] Termos MeSH primário: Fármacos Antiobesidade/uso terapêutico
Obesidade Pediátrica/prevenção & controle
Fentermina/uso terapêutico
Perda de Peso
[Mh] Termos MeSH secundário: Adolescente
Terapia Comportamental
Dieta Redutora
Feminino
Seres Humanos
Masculino
Minnesota/epidemiologia
Obesidade Pediátrica/terapia
Estudos Retrospectivos
Comportamento de Redução do Risco
Resultado do Tratamento
Perda de Peso/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Obesity Agents); C045TQL4WP (Phentermine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1038/ijo.2016.185


  2 / 760 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:28455281
[Au] Autor:Guo F; Garvey WT
[Ad] Endereço:Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX faguo@utmb.edu.
[Ti] Título:Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
[So] Source:Diabetes Care;40(7):856-862, 2017 07.
[Is] ISSN:1935-5548
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To assess the ability of medication-assisted weight loss to prevent diabetes as a function of the baseline weighted Cardiometabolic Disease Staging (CMDS) score. RESEARCH DESIGN AND METHODS: We pooled data from 3,040 overweight and obese participants in three randomized controlled trials-CONQUER, EQUIP, and SEQUEL-assessing efficacy and safety of phentermine/topiramate extended release (ER) for weight loss. In these double-blind phase III trials, overweight/obese adult patients were treated with a lifestyle intervention and randomly assigned to placebo versus once-daily oral phentermine/topiramate ER. The weighted CMDS score was calculated using baseline quantitative clinical data including waist circumference, blood glucose, blood pressure, and blood lipids. Incident diabetes was defined based on serial measures of fasting glucose, 2-h oral glucose tolerance test glucose, and/or HbA . RESULTS: The absolute decrease in 1-year diabetes incidence rates in subjects treated with medication versus placebo was greatest in those with high-risk CMDS scores at baseline (10.43-6.29%), intermediate in those with moderate CMDS risk (4.67-2.37%), and small in the low-risk category (1.51-0.67%). The number of participants needed to treat to prevent one new case of diabetes over a 56-week period was 24, 43, and 120 in those with baseline CMDS scores of ≥60, 30-59, and 0-29, respectively. CONCLUSIONS: Numbers needed to treat to prevent one case of type 2 diabetes are markedly lower in patients with high-risk scores. CMDS can be used to quantify risk of diabetes in overweight/obese individuals and predict the effectiveness of weight-loss therapy to prevent diabetes.
[Mh] Termos MeSH primário: Fármacos Antiobesidade/administração & dosagem
Diabetes Mellitus Tipo 2/prevenção & controle
Frutose/análogos & derivados
Obesidade/tratamento farmacológico
Fentermina/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Glicemia
Ensaios Clínicos Fase III como Assunto
Preparações de Ação Retardada/administração & dosagem
Diabetes Mellitus Tipo 2/sangue
Diabetes Mellitus Tipo 2/etiologia
Método Duplo-Cego
Feminino
Frutose/administração & dosagem
Seres Humanos
Estilo de Vida
Masculino
Meia-Idade
Obesidade/sangue
Obesidade/complicações
Circunferência da Cintura
Perda de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Anti-Obesity Agents); 0 (Blood Glucose); 0 (Delayed-Action Preparations); 0H73WJJ391 (topiramate); 30237-26-4 (Fructose); C045TQL4WP (Phentermine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.2337/dc17-0088


  3 / 760 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29156182
[Au] Autor:Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
[Ad] Endereço:Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, 1165 York Avenue, New York, NY 10065, USA. Electronic address: kph2001@med.cornell.edu.
[Ti] Título:Obesity Pharmacotherapy.
[So] Source:Med Clin North Am;102(1):135-148, 2018 Jan.
[Is] ISSN:1557-9859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Although diet, physical activity, and behavioral modifications are the cornerstones of weight management, weight loss achieved by lifestyle modifications alone is often limited and difficult to maintain. Pharmacotherapy for obesity can be considered if patients have a body mass index (BMI) of 30 kg/m or greater or BMI of 27 kg/m or greater with weight-related comorbidities. The 6 most commonly used antiobesity medications are phentermine, orlistat, phentermine/topiramate extended release, lorcaserin, naltrexone sustained release (SR)/bupropion SR, and liraglutide 3.0 mg. Successful pharmacotherapy for obesity depends on tailoring treatment to patients' behaviors and comorbidities and monitoring of efficacy, safety, and tolerability.
[Mh] Termos MeSH primário: Fármacos Antiobesidade/uso terapêutico
Obesidade/tratamento farmacológico
[Mh] Termos MeSH secundário: Benzazepinas/uso terapêutico
Combinação de Medicamentos
Frutose/análogos & derivados
Frutose/uso terapêutico
Seres Humanos
Lactonas/uso terapêutico
Naltrexona/uso terapêutico
Obesidade/prevenção & controle
Fentermina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Obesity Agents); 0 (Benzazepines); 0 (Drug Combinations); 0 (Lactones); 0H73WJJ391 (topiramate); 30237-26-4 (Fructose); 5S6W795CQM (Naltrexone); 637E494O0Z (lorcaserin); 95M8R751W8 (orlistat); C045TQL4WP (Phentermine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171212
[Lr] Data última revisão:
171212
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171121
[St] Status:MEDLINE


  4 / 760 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28378293
[Au] Autor:Gadde KM; Pritham Raj Y
[Ad] Endereço:Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins Rd, Baton Rouge, LA, 70810, USA. kishore.gadde@pbrc.edu.
[Ti] Título:Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
[So] Source:Curr Diab Rep;17(5):34, 2017 May.
[Is] ISSN:1539-0829
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE OF REVIEW: This review provides an overview of the current state of drug therapy for obesity, with a focus on four new drug therapies-lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide 3.0 mg-which have been approved by the US Food and Drug Administration (FDA) for long-term management of obesity since 2012. Topics discussed in this paper include rationale for pharmacotherapy, history of antiobesity drugs, and efficacy and safety data from randomized controlled trials with implications for clinical practice. RECENT FINDINGS: Weight loss achieved by currently approved drugs ranges from approximately 3 to 9%, above and beyond weight loss with lifestyle counseling alone, after a year. Response and attrition rates in clinical trials indicate that the benefits of pharmacotherapy range from substantial for some patients, modest for others, and no benefits for others still. Decisions regarding selection of a suitable drug from the available pharmacotherapy options and duration of treatment should be based on the expected and observed benefit-to-risk balance and tailored to the needs of each individual patient using the principles of shared decision-making.
[Mh] Termos MeSH primário: Fármacos Antiobesidade/uso terapêutico
Obesidade/tratamento farmacológico
[Mh] Termos MeSH secundário: Benzazepinas/uso terapêutico
Ensaios Clínicos como Assunto
Frutose/análogos & derivados
Frutose/uso terapêutico
Seres Humanos
Estilo de Vida
Liraglutida/uso terapêutico
Fentermina/uso terapêutico
Perda de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Obesity Agents); 0 (Benzazepines); 0H73WJJ391 (topiramate); 30237-26-4 (Fructose); 637E494O0Z (lorcaserin); 839I73S42A (Liraglutide); C045TQL4WP (Phentermine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170406
[St] Status:MEDLINE
[do] DOI:10.1007/s11892-017-0859-2


  5 / 760 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28289041
[Au] Autor:Hollander P; Bays HE; Rosenstock J; Frustaci ME; Fung A; Vercruysse F; Erondu N
[Ad] Endereço:Baylor University Medical Center, Dallas, TX priscilh@baylorhealth.edu.
[Ti] Título:Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.
[So] Source:Diabetes Care;40(5):632-639, 2017 May.
[Is] ISSN:1935-5548
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo (PBO) and CANA or PHEN monotherapies in individuals who were overweight and obese without type 2 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, phase 2a, randomized, double-blind, PBO-controlled, multicenter, parallel-group study enrolled individuals who were obese or overweight without type 2 diabetes ( = 335, aged 18-65 years, BMI ≥30 to <50 kg/m or BMI ≥27 to <50 kg/m with hypertension and/or dyslipidemia). Participants were randomized (1:1:1:1) to receive PBO, CANA 300 mg, PHEN 15 mg, or coadministration of CANA 300 mg and PHEN 15 mg (CANA/PHEN) orally once daily. The primary end point was percent change in body weight from baseline to week 26; key secondary end points were the proportion of participants achieving weight loss ≥5% and change from baseline in systolic blood pressure. RESULTS: CANA/PHEN provided statistically superior weight loss from baseline versus PBO at week 26 (least squares mean difference -6.9% [95% CI -8.6 to -5.2]; < 0.001). CANA/PHEN also provided statistically superior achievement of weight loss ≥5% and reduction in systolic blood pressure compared with PBO. CANA/PHEN was generally well tolerated, with a safety and tolerability profile consistent with that of the individual components. CONCLUSIONS: CANA/PHEN produced meaningful reductions in body weight and was generally well tolerated in individuals who were overweight or obese without type 2 diabetes. Further studies are warranted to evaluate potential use of this combination for long-term weight management.
[Mh] Termos MeSH primário: Depressores do Apetite/administração & dosagem
Canagliflozina/administração & dosagem
Hipoglicemiantes/administração & dosagem
Obesidade/tratamento farmacológico
Sobrepeso/tratamento farmacológico
Fentermina/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Depressores do Apetite/efeitos adversos
Pressão Sanguínea/efeitos dos fármacos
Canagliflozina/efeitos adversos
Diabetes Mellitus Tipo 2
Método Duplo-Cego
Feminino
Seres Humanos
Hipoglicemiantes/efeitos adversos
Masculino
Meia-Idade
Obesidade/complicações
Obesidade/fisiopatologia
Sobrepeso/complicações
Sobrepeso/fisiopatologia
Fentermina/efeitos adversos
Tiofenos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Appetite Depressants); 0 (Hypoglycemic Agents); 0 (Thiophenes); 0SAC974Z85 (Canagliflozin); C045TQL4WP (Phentermine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170315
[St] Status:MEDLINE
[do] DOI:10.2337/dc16-2427


  6 / 760 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28280086
[Au] Autor:Shao EX; Wilson GJ; Ranganathan D
[Ad] Endereço:University of Sydney, Sydney, New South Wales, Australia.
[Ti] Título:Phentermine induced acute interstitial nephritis.
[So] Source:BMJ Case Rep;2017, 2017 Mar 09.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Acute interstitial nephritis (AIN) has a number of medication-related aetiologies. Antibiotics, proton pump inhibitors and non-steroidal anti-inflammatory drugs are common causes; however, any medication has the potential to cause drug-induced AIN. We report the first case of phentermine-induced AIN. A Caucasian woman aged 43 years presented with a 5-week history of lethargy, left-sided lower abdominal pain, nausea and vomiting. She had been taking phentermine for weight loss for 9 months and had recently ceased the medication. The patient underwent a renal biopsy that showed a predominantly lymphohistiocytic interstitial infiltrate with a moderate number of eosinophils consistent with AIN. Phentermine is increasingly used for weight loss in obese patients. This is the first case implicating phentermine as the causative agent for drug-induced AIN. While rare, phentermine-induced AIN is a possible adverse reaction of phentermine. Physicians and patients need to be aware of this risk.
[Mh] Termos MeSH primário: Nefrite Intersticial/induzido quimicamente
Obesidade/tratamento farmacológico
Fentermina/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
C045TQL4WP (Phentermine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170320
[Lr] Data última revisão:
170320
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170311
[St] Status:MEDLINE


  7 / 760 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28246654
[Au] Autor:Curry SA
[Ad] Endereço:Division of Endocrinology, Diabetes and Metabolism, CharterCARE Medical Associates, Providence RI.
[Ti] Título:Obesity Epidemic: Pharmaceutical Weight Loss.
[So] Source:R I Med J (2013);100(2):18-20, 2017 Mar 01.
[Is] ISSN:2327-2228
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Obesity is a chronic disease universally defined as an excess of adipose tissue resulting in body mass index (BMI) > 30.0 kg/m2. Over the past few years, the concept of prevention has gained increased awareness, thus leading to the development of additional pharmaceutical options for the treatment of obesity since 2012. Treating obesity revolves around an individualized, multi-disciplinary approach with additional focus on a healthy and supportive lifestyle to maintain the weight loss. [Full article available at http://rimed.org/rimedicaljournal-2017-03.asp].
[Mh] Termos MeSH primário: Fármacos Antiobesidade/uso terapêutico
Obesidade/tratamento farmacológico
Perda de Peso/efeitos dos fármacos
[Mh] Termos MeSH secundário: Fármacos Antiobesidade/efeitos adversos
Benzazepinas/efeitos adversos
Benzazepinas/uso terapêutico
Índice de Massa Corporal
Bupropiona/efeitos adversos
Bupropiona/uso terapêutico
Combinação de Medicamentos
Frutose/efeitos adversos
Frutose/análogos & derivados
Frutose/uso terapêutico
Seres Humanos
Lactonas/efeitos adversos
Lactonas/uso terapêutico
Liraglutida/efeitos adversos
Liraglutida/uso terapêutico
Naltrexona/efeitos adversos
Naltrexona/uso terapêutico
Fentermina/efeitos adversos
Fentermina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Obesity Agents); 0 (Benzazepines); 0 (Drug Combinations); 0 (Lactones); 0 (Qsymia); 0 (bupropion hydrochloride, naltrexone hydrochoride drug combination); 01ZG3TPX31 (Bupropion); 30237-26-4 (Fructose); 5S6W795CQM (Naltrexone); 637E494O0Z (lorcaserin); 839I73S42A (Liraglutide); 95M8R751W8 (orlistat); C045TQL4WP (Phentermine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170602
[Lr] Data última revisão:
170602
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE


  8 / 760 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28192104
[Au] Autor:Igel LI; Kumar RB; Saunders KH; Aronne LJ
[Ad] Endereço:Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medical College, New York, New York. Electronic address: lei9004@med.cornell.edu.
[Ti] Título:Practical Use of Pharmacotherapy for Obesity.
[So] Source:Gastroenterology;152(7):1765-1779, 2017 May.
[Is] ISSN:1528-0012
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Obesity management requires a multidisciplinary approach, as there are many factors that contribute to the development of obesity, as well as the preservation of excess weight once it has been gained. Diet, exercise, and behavior modification are key components of treatment. In addition to lifestyle changes, weight gain secondary to medications is an important modifiable risk factor. Even after appropriate lifestyle modification, and medication adjustments (where possible) to avoid agents that can contribute to weight gain, many patients are still unable to achieve clinically meaningful weight loss. Pharmacotherapy for obesity management can fill an important role for these patients. This article will review medications that can lead to weight gain and potential alternatives, currently approved anti-obesity medications and best practices to individualize the selection process, and the use of testosterone in men with hypogonadism and obesity.
[Mh] Termos MeSH primário: Androgênios/uso terapêutico
Fármacos Antiobesidade/uso terapêutico
Bupropiona/uso terapêutico
Naltrexona/uso terapêutico
Obesidade/tratamento farmacológico
Testosterona/uso terapêutico
Ganho de Peso/efeitos dos fármacos
[Mh] Termos MeSH secundário: Fármacos Antiobesidade/administração & dosagem
Antidepressivos/efeitos adversos
Anti-Hipertensivos/efeitos adversos
Antipsicóticos/efeitos adversos
Depressores do Apetite/uso terapêutico
Benzazepinas/uso terapêutico
Bupropiona/administração & dosagem
Combinação de Medicamentos
Frutose/análogos & derivados
Frutose/uso terapêutico
Seres Humanos
Hipoglicemiantes/efeitos adversos
Hipogonadismo/complicações
Hipogonadismo/tratamento farmacológico
Lactonas/uso terapêutico
Liraglutida/uso terapêutico
Naltrexona/administração & dosagem
Obesidade/complicações
Fentermina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Androgens); 0 (Anti-Obesity Agents); 0 (Antidepressive Agents); 0 (Antihypertensive Agents); 0 (Antipsychotic Agents); 0 (Appetite Depressants); 0 (Benzazepines); 0 (Drug Combinations); 0 (Hypoglycemic Agents); 0 (Lactones); 0 (Naltrexone-Bupropion combination); 01ZG3TPX31 (Bupropion); 0H73WJJ391 (topiramate); 30237-26-4 (Fructose); 3XMK78S47O (Testosterone); 5S6W795CQM (Naltrexone); 637E494O0Z (lorcaserin); 839I73S42A (Liraglutide); 95M8R751W8 (orlistat); C045TQL4WP (Phentermine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170214
[St] Status:MEDLINE


  9 / 760 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27732121
[Au] Autor:Halpern B; Mancini MC
[Ad] Endereço:a Obesity Unit, Department of Endocrinology, Hospital das Clínicas , University of São Paulo (USP) , São Paulo , Brazil.
[Ti] Título:Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
[So] Source:Expert Opin Drug Saf;16(1):27-39, 2017 Jan.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Few studies on combination therapies for the treatment of obesity had been conducted until recently, when two fixed-dose combinations, bupropion-naltrexone ER fixed-dose combination and phentermine-topiramate ER titrated-dose combinations were evaluated in clinical studies that ultimately led to FDA approval. Areas covered: In this review, we discuss safety concerns about both combinations, the rationale and history of combination therapies for obesity (including phentermine plus fenfluramine), and possible future new combinations. Expert opinion: Combination therapies are a promising new area in obesity treatment, similar to what occurs with diabetes and hypertension. Safety assessment is highly important due to the high number of potential users on a chronic basis.
[Mh] Termos MeSH primário: Fármacos Antiobesidade/administração & dosagem
Obesidade/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Fármacos Antiobesidade/efeitos adversos
Fármacos Antiobesidade/uso terapêutico
Bupropiona/administração & dosagem
Bupropiona/efeitos adversos
Bupropiona/uso terapêutico
Preparações de Ação Retardada
Combinação de Medicamentos
Frutose/administração & dosagem
Frutose/efeitos adversos
Frutose/análogos & derivados
Frutose/uso terapêutico
Seres Humanos
Naltrexona/administração & dosagem
Naltrexona/efeitos adversos
Naltrexona/uso terapêutico
Fentermina/administração & dosagem
Fentermina/efeitos adversos
Fentermina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Obesity Agents); 0 (Delayed-Action Preparations); 0 (Drug Combinations); 0 (bupropion hydrochloride, naltrexone hydrochoride drug combination); 01ZG3TPX31 (Bupropion); 0H73WJJ391 (topiramate); 30237-26-4 (Fructose); 5S6W795CQM (Naltrexone); C045TQL4WP (Phentermine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170310
[Lr] Data última revisão:
170310
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161013
[St] Status:MEDLINE


  10 / 760 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27906152
[Ti] Título:In brief: Phentermine (Lomaira) for weight loss.
[So] Source:Med Lett Drugs Ther;58(1509):158, 2016 Dec 05.
[Is] ISSN:1523-2859
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Fármacos Antiobesidade/uso terapêutico
Aprovação de Drogas
Fentermina/uso terapêutico
Perda de Peso/efeitos dos fármacos
[Mh] Termos MeSH secundário: Fármacos Antiobesidade/farmacologia
Aprovação de Drogas/legislação & jurisprudência
Seres Humanos
Obesidade/diagnóstico
Obesidade/tratamento farmacológico
Fentermina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Obesity Agents); C045TQL4WP (Phentermine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170201
[Lr] Data última revisão:
170201
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161202
[St] Status:MEDLINE



página 1 de 76 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde